References
- Lassen J F, Lassen N F, Skov F. [Consumption of psilocybin-containing hallucinogenic mushrooms by youngpeople]. Ugeskr Laeger 1992; 154: 2678–2681
- Schwartz R H, Smith D E. Hallucinogenic mushrooms. Clin Pediatr Phila 1988; 27: 70–73
- Spitzer M, Thimm M, Hermle L, et al. Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry 1996; 39: 1055–1057
- Hanes K R. Serotonin, psilocybin, and body dysmorphic disorder: A case report. J Clin Psychopharmacol 1996; 16: 188–189
- Gartz J. Extraction and analysis of indole derivatives from fungal biomass. J Basic Microbiol 1994; 34: 17–22
- Buckholtz N S, Zhou D F, Freedman D X, Potter W Z. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain. Neuropsychopharmacology 1990; 3: 137–148
- Franz M, Regele H, Kirchmair M, et al. Magic mushrooms: Hope for a “cheap high” resulting in end-stage renal failure. Nephrol Dial Transplant 1996; 11: 2324–2327
- Dreisbach R H, Robertson W O. Vademecum intoxications. Handbook of Poisoning: Prevention, Diagnosis and Treatment, 3rd Polish ed. PZWL, Warsaw 1995; 451–452, (translation). [Norwalk, CT: Appleton & Lange, 1987]
- Craig C R, Stitzel R E. Modern Pharmacology. Little Brown Co, Boston 1982; 592–595
- Raff E, Halloran P F, Kjellstrand C M. Renal failure after eating “magic” mushrooms. Can Med Assoc J 1992; 147: 1339–1341
- Kostkowski W, Puzynski S. Experimental Psycho-pharmacology. PZWL, Warsaw 1992; 422–428